Delivery Order SPE2DB24D2106-SPE2DB25FAVDZ

Award Date 5/1/25
Potential Completion Date 5/2/25
Potential Value $5.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,575.48 contract covers the supply of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML, a specialized pharmaceutical product, with a period of performance ending on November 22, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,671.91, is for the provision of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of January 17, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $6,717.31, is for the delivery of pharmaceutical products, including a specific item described as "4567925342 ! ZEPBOUND 5 MG/0.5 ML PEN 0.5ML". The contract is a firm fixed-price delivery order, with an ultimate completion date of April 16, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery...
This federal contract award is a delivery order valued at $5,445.50 that was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is a firm fixed-price agreement to provide a specific pharmaceutical product, ZEPBOUND 10 MG/0.5 ML PEN 0.5ML, to support the medical supply needs of military healthcare facilities. The contract has an ultimate completion date of February 12, 2025. DMS Pharmaceutical Group...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,906.45, is for the delivery of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of December 30, 2024. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the...
This federal contract award is to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML to the Defense Logistics Agency (DLA). The contract is a firm fixed-price delivery order valued at $8,873.25 with a completion date of January 8, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $3,685.50, is for the delivery of a specialty pharmaceutical product called ZEPBOUND 5 MG/0.5 ML PEN 0.5ML. It is a part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group, valued at $499,999,999, which enables the DLA to issue delivery orders for a comprehensive...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,705.03 contract is for the delivery of ZEPBOUND 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with an ultimate completion date of April 1, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,632.89 award is for the supply of ZEPBOUND 10 MG/0.5 ML PEN 0.5ML, a specialized pharmaceutical product, with a period of performance through March 7, 2025. DMS Pharmaceutical Group has a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,211.30, is for the supply of ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of November 19, 2024. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery...
  • SPE2DB24D2106
    Indefinite Delivery Contract
  • SPE2DB24D2106-SPE2DB25FAVDZ
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $5,538.02, is for the delivery of 4568104148 ! ZEPBOUND 5 MG/0.5 ML PEN 0.5ML, with a performance period ending on May 2, 2025. This is a firm fixed-price delivery order contract, without any set-aside designation.

DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories.

Generated 7/31/25, 10:08 AM